Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026
Same author

Fibroblasts hold the key to TLS formation.

Immunity·2026
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

Transcription-independent induction of rapid-onset senescence is integral to healing.

Nature cell biology·2026
Same author

TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients.

Translational lung cancer research·2026
Same journal

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Cancer metastasis reviews·2026
Same journal

Resolving translational challenges in cancer biology through yeast experimental evolution.

Cancer metastasis reviews·2026
Same journal

Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.

Cancer metastasis reviews·2026
Same journal

Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.

Cancer metastasis reviews·2026
Same journal

The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities.

Cancer metastasis reviews·2026
Same journal

Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress.

Cancer metastasis reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
09:52

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication

Published on: September 20, 2016

Tumor microenvironment is multifaceted.

Catherine Sautès-Fridman1, Julien Cherfils-Vicini, Diane Damotte

  • 1Centre de Recherche des Cordeliers, Team 13, Institut National de la Santé et de la Recherche Médicale U872, 15 rue de l'Ecole de Médecine, Paris 75006, France. catherine.fridman@crc.jussieu.fr

Cancer Metastasis Reviews
|January 29, 2011
PubMed
Summary
This summary is machine-generated.

Infectious agents and immune cell organization in the tumor microenvironment significantly impact Non-Small Cell Lung Cancer (NSCLC) progression. Dendritic cell (DC) subsets in early-stage NSCLC predict survival, suggesting potential for in situ immune activation.

More Related Videos

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Related Experiment Videos

Last Updated: Jun 4, 2026

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
09:52

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication

Published on: September 20, 2016

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
06:05

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Area of Science:

  • Oncology
  • Immunology
  • Cancer Microenvironment Research

Background:

  • Tumor progression is influenced by the host and site-specific microenvironment, including inflammatory contexts from infections.
  • Immunoprivileged sites harbor tumors in immunosuppressive environments, contrasting with mucosal tissues potentially affected by infections.
  • The role of Toll-like receptor (TLR) signaling and immune cell infiltration in Non-Small Cell Lung Cancer (NSCLC) progression requires further elucidation.

Purpose of the Study:

  • To review recent data on the influence of infectious context and immune cell organization on human NSCLC progression.
  • To investigate the direct effects of TLR stimulation on tumor cells regarding survival and chemotherapy response.
  • To assess the prognostic value of dendritic cell (DC) subsets in early-stage NSCLC patients.

Main Methods:

  • Analysis of TLR stimulation effects (TLR7/8, TLR4, TLR3) on lung tumor cell lines' viability and chemosensitivity.
  • Gene expression profiling of fresh lung tumor cells compared to TLR-stimulated cell lines.
  • Immunohistochemical analysis of mature and immature DC subsets (Langerhans cells, interstitial DCs) in 74 early-stage NSCLC patient tumors.
  • Evaluation of DC subset densities as predictors of disease-specific survival.

Main Results:

  • TLR stimulation by viral ssRNA (TLR7/8) or bacteria (TLR4) promotes tumor cell survival and chemoresistance.
  • TLR3 stimulation decreases tumor cell viability and can induce chemosensitivity in certain lung tumor cell lines.
  • Fresh lung tumor cells show gene expression profiles similar to TLR-stimulated cells, suggesting direct microbial influence.
  • Densities of mature DCs, Langerhans cells (LCs), and interstitial DCs (intDCs) in NSCLC stroma and tumor nests are highly predictive of disease-specific survival.
  • Evidence suggests immature DCs, particularly LCs, may migrate and mature within tertiary lymphoid structures, sampling tumor antigens.

Conclusions:

  • The infectious context and immune cell organization within the tumor microenvironment profoundly influence NSCLC progression and response to therapy.
  • Specific TLR signaling pathways can directly impact tumor cell behavior, affecting survival and chemotherapy sensitivity.
  • The density of distinct DC subsets in early-stage NSCLC is a significant prognostic biomarker, indicating potential for in situ adaptive immune activation.